Kindred Biosciences, Inc. (NASDAQ:KIN) – Investment analysts at B. Riley issued their FY2017 earnings per share estimates for Kindred Biosciences in a research note issued on Monday. B. Riley analyst A. D’silva expects that the biopharmaceutical company will earn ($1.16) per share for the year. B. Riley has a “Buy” rating and a $11.00 price objective on the stock. B. Riley also issued estimates for Kindred Biosciences’ Q4 2017 earnings at ($0.29) EPS, Q1 2018 earnings at ($0.32) EPS, Q2 2018 earnings at ($0.36) EPS, Q3 2018 earnings at ($0.35) EPS, Q4 2018 earnings at ($0.35) EPS, FY2018 earnings at ($1.37) EPS, FY2019 earnings at ($0.93) EPS and FY2020 earnings at ($0.28) EPS.

Kindred Biosciences (NASDAQ:KIN) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.04.

TRADEMARK VIOLATION NOTICE: This story was reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/kindred-biosciences-inc-kin-expected-to-earn-fy2017-earnings-of-1-16-per-share/1719155.html.

Other research analysts have also recently issued reports about the company. Zacks Investment Research raised Kindred Biosciences from a “hold” rating to a “buy” rating and set a $8.50 price target on the stock in a report on Wednesday, September 6th. HC Wainwright started coverage on Kindred Biosciences in a report on Friday, November 17th. They issued a “buy” rating and a $9.50 price target on the stock. Three analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $9.54.

Kindred Biosciences (NASDAQ KIN) opened at $7.50 on Wednesday. Kindred Biosciences has a twelve month low of $3.90 and a twelve month high of $9.65.

A number of large investors have recently added to or reduced their stakes in KIN. Virtu KCG Holdings LLC increased its position in shares of Kindred Biosciences by 41.7% during the 2nd quarter. Virtu KCG Holdings LLC now owns 15,285 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 4,495 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Kindred Biosciences by 28.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 22,336 shares of the biopharmaceutical company’s stock valued at $157,000 after acquiring an additional 4,954 shares during the last quarter. Wells Fargo & Company MN grew its position in Kindred Biosciences by 2.2% in the 3rd quarter. Wells Fargo & Company MN now owns 337,608 shares of the biopharmaceutical company’s stock valued at $2,650,000 after acquiring an additional 7,206 shares during the last quarter. Prudential Financial Inc. grew its position in Kindred Biosciences by 18.9% in the 3rd quarter. Prudential Financial Inc. now owns 52,920 shares of the biopharmaceutical company’s stock valued at $415,000 after acquiring an additional 8,410 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in Kindred Biosciences by 17.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 74,548 shares of the biopharmaceutical company’s stock valued at $586,000 after acquiring an additional 11,081 shares during the last quarter. 61.77% of the stock is currently owned by institutional investors and hedge funds.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.

Earnings History and Estimates for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.